A Review of Breast Cancer Cases Experiencing Ki-67 Expressions
Main Article Content
The main purposes of Ki-67 examination today are prognosis estimation, choice of adjuvant therapy, and response prediction to neoadjuvant therapy.
Thus, it is vital that the pathologist accurately and reliably assesses the Ki-67 status of breast cancer. In order to determine the relationship between Ki-67 status and known prognostic factors like age, tumor size, histological type, and grade, axillary lymph node metastasis, lymph vascular invasion (tumor emboli), tumor necrosis, hormone receptors such as estrogen receptor (ER) and progesterone receptor (PR), Her-2 neu status, and molecular subtypes (Luminal A, Luminal B, Her 2 neu enriched, and triple-negative). Hence, diverse combinations of surgery, hormone therapy, postoperative radiation, and chemotherapy make up the current therapeutic approaches for treating breast cancer. A key duty of the clinician is to choose between hormone therapy, which has few side effects, and chemotherapy, which carries known morbidity and risk.
BiganzoliL.Prognostic and predictive factors. In: Castiglione M,PiccartM editor. Adjuvant Therapy for Breast Cancer. Cancer TreatmentandResearch, vol 151. Boston: Springer; 2009: 13 – 30.
Page DL, Ellis IO, Elston CW. Histologic grading of breast cancer: Let'sdo it. A JC P. 1995 Feb:123-124.
Schnitt SJ, Collins LC. Invasive breast cancer. In: Biopsy Interpretation of the Breast. 2nd ed. Philadelphia: Lippincott Williams &Wilkins;2013:282-351.
Schwartz AM, Henson DE, Chen D, Rajamarthandans. Histologicgrade remains a prognostic factor for breast cancer regardless of thenumber of positive lymph nodes and tumor size: A study of 161708cases of breast cancer from the SEER program. Arch Patho Lab Med.2014; 138:1048-1052.
Doussal VL, Hulin MT, Freidman S, Hacene K, Spyratos F, Brunet M.Prognostic value of histologlc grade nuclear components of scarfbloom-richardson (SBR): An improved score modification based on amultivariate analysis of 1262 invasive ductal breast carcinomas.Cancer. 1989; 64:1914-1921.
Shaikh F, Jamal Q, Baig S, Hadi NI, Majeed N. Correlation of hormonereceptor and HER-2/neu expression with clinicopathologicalparameters in primary breast tumors. Asian Pac J Cancer Prev. 2016;17(7): 3363-3367.
Lowery AJ, Sweeney KJ. The role of prophylactic oophorectomy in themanagement of hereditary breast & ovarian cancer syndrome. In: Al-Hendy A, Sabry M. Hysterectomy: lnTech, 2012: 345-364.
Singh G. Oophorectomy in breast cancer - Controversies and currentstatus. Indian J Surg 2012; 74(3):210-212.
Duffy MJ. Biochemical markers as prognostic indices in breast cancer.ClinChem.1990; 36(2)186-191.
Corben AD, Brogi E. Ductal carcinoma In situ and other Intraductallesions: Pathology, Immunohistochemistry, and Molecular alterations.In: Harris JR, Lippman ME, Morrow M, Osborne CK. Disease of thebreast. 5th ed. Philadelphia: Wolters Kluwer ; 2014: 309 - 322.
Goncalves R, Cakar B, Bose R, Ma CX, Ellis MJ. Genomic events inbreast cancer progression. In: Harris JR, Lippman ME, Morrow M,Osborne CK. Disease of the breast. 5th ed. Philadelphia: WoltersKluwer; 2014: 361-378.
Siadati S, Sharbatdaran M, Nikbakhsh N, Ghaemian N. Correlation ofER, PR and HER-2/Neu with other prognostic factors in infiltratingductal carcinoma of breast. Iran J Pathol. 2015; 10(3):221-226.
Dowsett M, Miller W. Estrogen and progesterone receptor testing forprognosis and prediction. In: Harris JR, Lippman ME, Morrow M,Osborne CK. Disease of the breast. 5th ed. Philadelphia: WoltersKluwer; 2014: 411- 421.
Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen andprogesterone receptors and histologic features in 3,655 invasive breastcarcinomas. Am J Clin Pathol. 2005 ; 123:541-546.
Alfred DC. Should immunohistochemical examination replacebiochemical hormone receptor assays in breast cancer. Am J ClinPathol. 1993; 99(1): 1- 3.
Gerdes J, Schwab U, Lemke H, Stein H. Production of a mousemonoclonal antibody reactive with a human nuclear antigen associatedwith cell proliferation. Int J Cancer, 1983;31 (1):13-20.
Fonatsch C, Duchrow M, Rieder H, Schluter C, Gerdes J. Assignmentof the human Ki-67 gene (MK167) to 10q25-qter. Genomics, 1991;11(2):476-477.
Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD,et al. The cell proliferation-associated antigen of antibody Ki-67: a verylarge, ubiquitous nuclear protein with numerous repeated elements,representing a new kind of cell cycle-maintaining proteins. J Cell Biol,1993;123 (3):513-522.
Duchrow M, Schluter C, Wohlenberg C, Flad HD, Gerdes J. Molecularcharacterization of the gene locus of the human cell proliferationassociatednuclear protein defined by monoclonal antibody Ki-67. CellProlif, 1996;29 (1):1-12.